NASDAQ:VALN

Valneva (VALN) Stock Forecast, Price & News

$11.36

-0.25 (-2.15%)

(As of 09/28/2023 ET)

Compare

Today's Range: $11.33
▼
$12.07
50-Day Range: $11.36
▼
$15.29
52-Week Range: $9.07
▼
$17.05

Volume: 9,071 shs
Average Volume: 5,521 shs
Market Capitalization: $789.07 million

P/E Ratio: 81.14
Dividend Yield: N/A
Price Target: $22.00

Valneva MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 93.7% Upside
$22.00 Price Target
Short Interest: Healthy
0.01% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.18
Based on 12 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.48) to ($0.80) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars

Medical Sector

435th out of 969 stocks

Biological Products, Except Diagnostic Industry

65th out of 161 stocks

3.5

Analyst's Opinion

Consensus Rating
Valneva has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $22.00, Valneva has a forecasted upside of 93.7% from its current price of $11.36.
Amount of Analyst Coverage
Valneva has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.01% of the float of Valneva has been sold short.
Short Interest Ratio / Days to Cover
Valneva has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Valneva has recently increased by 24.53%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Valneva does not currently pay a dividend.
Dividend Growth
Valneva does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for VALN.

2.9

News and Social Media Coverage

News Sentiment
Valneva has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 12 news articles for Valneva this week, compared to 2 articles on an average week.
Search Interest
1 people have searched for VALN on MarketBeat in the last 30 days.
MarketBeat Follows
4 people have added Valneva to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Valneva insiders have not sold or bought any company stock.
Percentage Held by Insiders
14.91% of the stock of Valneva is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 18.98% of the stock of Valneva is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Valneva are expected to decrease in the coming year, from ($0.48) to ($0.80) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Valneva is 81.14, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 124.10.
Price to Earnings Ratio vs. Sector
The P/E ratio of Valneva is 81.14, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 151.41.
Price to Book Value per Share Ratio
Valneva has a P/B Ratio of 3.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Valneva (NASDAQ:VALN) Stock

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.

VALN Price History

30 days | 90 days | 365 days | Advanced Chart

VALN Stock News Headlines

September 29, 2023 | americanbankingnews.com

Valneva (NASDAQ:VALN) Receives "Buy" Rating from Needham & Company LLC

September 28, 2023 | americanbankingnews.com

Valneva (NASDAQ:VALN) Stock Rating Reaffirmed by HC Wainwright

September 29, 2023 | Stansberry Research (Ad)

1907, 1929, 1998, 2007--and now 2023?

Analyst who called Lehman Bros. collapse says exact same scenario that occurred in 4 of America’s biggest economic calamities is unfolding again now. More here.

September 27, 2023 | finance.yahoo.com

Valneva SE (NASDAQ:VALN) Q2 2023 Earnings Call Transcript

September 25, 2023 | markets.businessinsider.com

Buy Rating for Valneva: Future Prospects and Financial Analysis

September 25, 2023 | msn.com

Valneva receives JE vaccine supply contract from US DoD

September 25, 2023 | msn.com

Valneva gets new $32M supply contract for the U.S. government

September 25, 2023 | finance.yahoo.com

Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32 Million

September 29, 2023 | Stansberry Research (Ad)

1907, 1929, 1998, 2007--and now 2023?

Analyst who called Lehman Bros. collapse says exact same scenario that occurred in 4 of America’s biggest economic calamities is unfolding again now. More here.

September 21, 2023 | msn.com

U.S. FDA found lapses at Novo's main U.S. factory in May 2022 -report

September 21, 2023 | markets.businessinsider.com

Valneva Reports Half Year 2023 Financial Results and Provides Corporate Updates

September 21, 2023 | marketwatch.com

Valneva Loss Narrows on Reduced Costs

September 21, 2023 | msn.com

Valneva's half-year loss narrows on strong travel vaccine demand

September 21, 2023 | finance.yahoo.com

Valneva Reports Half Year 2023 Financial Results and Provides Corporate Updates

September 8, 2023 | msn.com

Pfizer Lyme Disease Vaccine Shows Promise

September 7, 2023 | markets.businessinsider.com

Analyst Ratings for Valneva

September 7, 2023 | markets.businessinsider.com

Valneva Reports Positive Pediatric & Adolescent Phase 2 Booster Results For Lyme Disease Vaccine

September 6, 2023 | finance.yahoo.com

VALNEVA Declaration of shares and voting rights: August 31, 2023

August 31, 2023 | finance.yahoo.com

Valneva to Participate in Investor Conferences in the United States and Europe in September 2023

August 29, 2023 | msn.com

Health Canada accepts Valneva’s chikungunya vaccine filing for review

August 29, 2023 | markets.businessinsider.com

Canada Accepts Valneva's Chikungunya Vaccine License Application For Review

August 29, 2023 | tmcnet.com

Health Canada Accepts Valneva's Chikungunya Vaccine License Application for Review

August 29, 2023 | finance.yahoo.com

Health Canada Accepts Valneva’s Chikungunya Vaccine License Application for Review

August 28, 2023 | finanznachrichten.de

VALNEVA: Valneva Reports Positive Initial Phase 3 Safety Data in Adolescents for its Single-Shot Chikungunya Vaccine Candidate

August 28, 2023 | markets.businessinsider.com

Valneva Reports Positive Safety Data In Adolescents For Chikungunya Vaccine Candidate

August 28, 2023 | marketwatch.com

Valneva Gets Positive Data in Chikungunya Vaccine Trial

August 28, 2023 | msn.com

Valneva reports data from chikungunya vaccine trial in adolescents

See More Headlines

Receive VALN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Valneva and its competitors with MarketBeat's FREE daily newsletter.

VALN Company Calendar

Today: 9/29/2023
Next Earnings (Estimated): 11/09/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:VALN
CUSIP: N/A
CIK: 1836564
Web: valneva.com
Phone: 33-2-28-07-37-10
Fax: N/A
Employees: 719
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $22.00
High Stock Price Forecast: $22.00
Low Stock Price Forecast: $22.00
Forecasted Upside/Downside: +93.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.14
Trailing P/E Ratio: 81.14
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-150,960,000.00
Net Margins: -2.85%
Pretax Margin: -40.08%
Return on Equity: -4.86%
Return on Assets: -1.51%

Debt

Debt-to-Equity Ratio: 0.41
Current Ratio: 1.48
Quick Ratio: 1.33

Sales & Book Value

Annual Sales: $380.73 million
Price / Sales: 2.07
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.35 per share
Price / Book: 3.39

Miscellaneous

Outstanding Shares: 69,460,000
Free Float: 59,100,000
Market Cap: $789.07 million
Optionable: Not Optionable
Beta: 2.69

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Mr. Thomas Lingelbach (Age 60)
Chairman of the Management Board, Pres & CEO
Comp: $853.43k

Mr. Peter Buhler (Age 52)
CFO & Management Board Member
Comp: $566.26k

Mr. Franck Grimaud MBA (Age 56)
Director Gen., Chief Bus. Officer & Member of Management Board
Comp: $423.93k

Mr. Frederic Jacotot (Age 58)
VP of Legal & IP, Gen. Counsel, Corp. Sec. and Member of Management Board
Comp: $325.04k

Dr. Juan-Carlos Jaramillo M.D. (Age 51)
Chief Medical Officer & Member of the Management Board
Comp: $514.58k

Ms. Dipal Patel (Age 49)
Chief Commercial Officer & Member of Management Board
Comp: $826.98k

Mr. Perry Celentano
Interim Chief Operating Officer

Mr. Joshua Drumm Ph.D.
VP of Investor Relations

Ms. Laetitia Bachelot-Fontaine
VP of Global Communications & European Investor Relations

Mr. Gerald Strohmaier
VP of Human Resource

Key Competitors

View All Competitors

VALN Stock - Frequently Asked Questions

Should I buy or sell Valneva stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Valneva in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VALN shares.
View VALN analyst ratings or view top-rated stocks.
What is Valneva's stock price forecast for 2023?: 2 brokerages have issued twelve-month price targets for Valneva's stock. Their VALN share price forecasts range from $22.00 to $22.00. On average, they predict the company's share price to reach $22.00 in the next year. This suggests a possible upside of 93.7% from the stock's current price.
View analysts price targets for VALN or view top-rated stocks among Wall Street analysts.
How have VALN shares performed in 2023?: Valneva's stock was trading at $12.72 at the start of the year. Since then, VALN stock has decreased by 10.7% and is now trading at $11.3601.
View the best growth stocks for 2023 here.
Are investors shorting Valneva?: Valneva saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 6,600 shares, an increase of 24.5% from the August 31st total of 5,300 shares. Based on an average trading volume of 5,100 shares, the days-to-cover ratio is presently 1.3 days. Approximately 0.0% of the shares of the company are short sold.
View Valneva's Short Interest.
When is Valneva's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our VALN earnings forecast.
What guidance has Valneva issued on next quarter's earnings?: Valneva issued an update on its FY 2023 earnings guidance on Thursday, September, 21st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $239.78 million-$283.38 million, compared to the consensus revenue estimate of $180.50 million.

When did Valneva IPO?: (VALN) raised $99 million in an IPO on Thursday, May 6th 2021. The company issued 3,500,000 shares at a price of $28.24 per share. Goldman Sachs, Jefferies, Guggenheim Securities and Bryan, Garnier & Co. acted as the underwriters for the IPO.
What is Valneva's stock symbol?: Valneva trades on the NASDAQ under the ticker symbol "VALN."
How do I buy shares of Valneva?: Shares of VALN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Valneva's stock price today?: One share of VALN stock can currently be purchased for approximately $11.36.
How much money does Valneva make?: Valneva (NASDAQ:VALN) has a market capitalization of $789.07 million and generates $380.73 million in revenue each year. The company earns $-150,960,000.00 in net income (profit) each year or $0.14 on an earnings per share basis.
How many employees does Valneva have?: The company employs 719 workers across the globe.
How can I contact Valneva?: The official website for the company is valneva.com. The company can be reached via phone at 33-2-28-07-37-10 or via email at investors@valneva.com.

This page (NASDAQ:VALN) was last updated on 9/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial